Upstart Chinese drug innovators are joining their foreign competitors in deploying more artificial intelligence (AI) tools to reduce the costs of discoveries in an effort to shorten the route to clinical trials and commercialisation.
Genscript Biotech, based in Nanjing in eastern Jiangsu province, is developing in-house AI tools – using its enzyme prediction database and an algorithm for altering the DNA sequence of a gene – to identify and optimise promising candidates based on protein…

Read More